{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T15:05:45Z","timestamp":1749567945858,"version":"3.38.0"},"reference-count":41,"publisher":"Georg Thieme Verlag KG","issue":"03","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Endocrinol Diabetes"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent studies have suggested that improved\n                        glycemic control in patients with diabetes may cause acute Charcot foot. To\n                        conduct a narrative review of studies investigating whether improved\n                        glycemic control in patients with diabetes causes acute Charcot\n                    foot.<\/jats:p><jats:p>Publications found by searching PubMed, EMBASE, and\n                        Cochrane Library as well as reference lists of identified publications were\n                        reviewed.<\/jats:p><jats:p>Very few publications were found, primarily\n                        consisting of case reports and case studies without control groups,\n                        documenting instances where cases of acute Charcot foot had been preceded by\n                        improved glycemic control. Recent large multicenter randomized\n                        placebo-controlled clinical trials of anti-hyperglycemic agents in patients\n                        with diabetes, where significant improvement of glycemic control occurred,\n                        have not reported incidences of acute Charcot foot.<\/jats:p><jats:p>There is so far no solid evidence to suggest that\n                        improvement of glycemic control in patients with diabetes causes acute\n                        Charcot foot.<\/jats:p>","DOI":"10.1055\/a-2498-6826","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T23:43:46Z","timestamp":1737589426000},"page":"120-132","source":"Crossref","is-referenced-by-count":1,"title":["Does Improvement of Glycemic Control Cause Acute Charcot Foot in\n                    Patients with Diabetes?"],"prefix":"10.1055","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2846-9532","authenticated-orcid":false,"given":"Ole Lander","family":"Svendsen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Copenhagen Diabetes Foot\n                    Center, Bispebjerg Frederiksberg University Hospital, Copenhagen,\n                    Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen,\n                    Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasmus Bo","family":"Jansen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Copenhagen Diabetes Foot\n                    Center, Bispebjerg Frederiksberg University Hospital, Copenhagen,\n                    Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.2337\/dc11-0844","article-title":"The Charcot foot in diabetes","volume":"34","author":"L C Rogers","year":"2011","journal-title":"Diabetes Care"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.2337\/dc20-2590","article-title":"How common is the rare Charcot foot in patients with diabetes","volume":"44","author":"O L Svendsen","year":"2021","journal-title":"Diabetes Care"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jdiacomp.2018.09.013","article-title":"Mortality and complications after treatment of acute diabetic Charcot foot","volume":"32","author":"R B Jansen","year":"2018","journal-title":"J Diabetes Complications"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jdiacomp.2018.04.010","article-title":"A review of bone metabolism and developments in medical treatment of the\n                    diabetic Charcot foot","volume":"32","author":"R B Jansen","year":"2018","journal-title":"J Diabetes Complications"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jdiacomp.2017.11.004","article-title":"Bone mineral density and markers of bone turnover and inflammation in diabetes\n                    patients with or without a Charcot foot: An 8.5-year prospective case-control\n                    study","volume":"32","author":"R B Jansen","year":"2018","journal-title":"J Diabetes Complications"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.tem.2022.12.003","article-title":"Trends in the pathophysiology of Charcot neuroarthropathy","volume":"34","author":"D Dardari","year":"2023","journal-title":"Trends Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3390\/pharmaceutics15071791","article-title":"Impact of intensive glycemic treatment on diabetes complications \u2013 a systematic\n                    review","volume":"15","author":"J Poonoosamy","year":"2023","journal-title":"Pharmaceutics"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e0233168","DOI":"10.1371\/journal.pone.0233168","article-title":"Rapid glycemic regulation in poorly controlled patients living with diabetes, a\n                    new associated factor in the pathophysiology of Charcot\u2019s acute\n                    neuroarthropathy","volume":"15","author":"D Dardari","year":"2020","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"e002380","DOI":"10.1136\/bmjdrc-2021-002380","article-title":"Trends in the relation between hyperglycemia correction and active Charcot\n                    neuroarthropathy: Results from the EPICHAR study","volume":"10","author":"D Dardari","year":"2022","journal-title":"BMJ Open Diab Res Care"},{"key":"ref10","first-page":"20","article-title":"The onset of acute Charcot neuroarthropathy during pregnancy in type 1\n                    diabetes","volume":"2020","author":"D Dardari","year":"2020","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"107348","DOI":"10.1016\/j.jdiacomp.2019.107438","article-title":"Multifocal (tarsus and knee) activation of neuroarthropathy following rapid\n                    glycaemic correction","volume":"33","author":"D Dardari","year":"2019","journal-title":"J Diabetes Complications"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.4239\/wjd.v14.i11.1710","article-title":"Rapid correction of Hyperglycemia: A necessity but at what price? A brief report\n                    of a patient living with type 1 diabetes","volume":"14","author":"P Huret","year":"2023","journal-title":"World J Diabetes"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"522","DOI":"10.7547\/0003-0538-104.5.522","article-title":"The development of a Charcot foot after significant weight loss in people with\n                    diabetes: Three cautionary tales","volume":"104","author":"R Murchison","year":"2014","journal-title":"J Am Podiatr Med Assoc"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.2337\/dc11-0960","article-title":"Immunosuppression therapy posttransplantation can be associated with a different\n                    clinical phenotype for diabetic Charcot foot neuroarthropathy","volume":"34","author":"J Valabhji","year":"2011","journal-title":"Diabetes Care"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3402\/dfa.v4i0.21819","article-title":"Charcot neuroarthropathy in simultaneous kidney-pancreas transplantation: Report\n                    of two cases","volume":"4","author":"J J Vecchio","year":"2013","journal-title":"Diabet Foot Ankle"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/01.tp.0000244730.95416.c6","article-title":"High rate of Charcot foot Attacks early after simultaneous pancreas-kidney\n                    transplantation","volume":"83","author":"G Matricali","year":"2007","journal-title":"Transplantation"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/ctr.12572","article-title":"Charcot neuropathy after simultaneous pancreas-kidney transplantation: Risk\n                    factors, prevalence, and outcome","volume":"29","author":"F Garcia Barrado","year":"2015","journal-title":"Clin Transplant"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/TP.0b013e31825cadbb","article-title":"Charcot neuroarthropathy after simultaneous pancreas-kidney transplant","volume":"94","author":"\u00c9B Rangel","year":"2012","journal-title":"Transplantation"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1053\/j.jfas.2018.09.022","article-title":"Development of Charcot neuroarthropathy in diabetic patients who received kidney\n                    or kidney-pancreas transplants","volume":"58","author":"M L Anthony","year":"2019","journal-title":"J Foot Ankle Surgery"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1002\/jbmr.113","article-title":"Glucocorticoids maintain human osteoclasts in the active mode of their\n                    resorption cycle","volume":"25","author":"K S\u00f8e","year":"2010","journal-title":"J Bone Miner Res"},{"key":"ref21","first-page":"6640796","article-title":"Potential metabolic pathways involved in osteoporosis and evaluation of fracture\n                    risk in individuals with diabetes","volume":"2024","author":"T Liu","year":"2024","journal-title":"BioMed Res Int"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11914-014-0202-7","article-title":"Diabetes, collagen and bone quality","volume":"12","author":"M Saito","year":"2014","journal-title":"Curr Osteoporos Rep"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.2337\/dc19-1659","article-title":"Effect of methylprednisolone or zoledronic acid on resolution of active Charcot\n                    neuroarthropathy in Diabetes: A randomized, double-blind, placebo-controlled\n                    study","volume":"42","author":"L Das","year":"2019","journal-title":"Diabetes Care"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/dme.12590","article-title":"Inflammatory and bone turnover markers in a cross-sectional and prospective\n                    study of acute Charcot osteoarthropathy","volume":"32","author":"N L Petrova","year":"2015","journal-title":"Diabet Med"},{"key":"ref25","first-page":"1234","article-title":"Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic\n                    patients","volume":"87","author":"G D Xiang","year":"2007","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1530\/eje.1.02049","article-title":"Plasma osteoprotegerin levels are associated with glycemic status, systolic\n                    blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic\n                    patients","volume":"154","author":"L M Rasmussen","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"ref27","first-page":"631","article-title":"Associations of serum osteoprotegerin levels with diabetes, stroke, bone\n                    density, fractures, and mortality in elderly women","volume":"86","author":"W S Browner","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.2337\/diacare.28.9.2176","article-title":"Osteoprotegerin is associated with silent coronary artery disease in high-risk\n                    but asymptomatic type 2 diabetic patients","volume":"28","author":"A Avignon","year":"2005","journal-title":"Diabetes Care"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.jacc.2005.12.054","article-title":"The relationship between plasma osteoprotegerin levels and coronary artery\n                    calcification in uncomplicated type 2 diabetic subjects","volume":"47","author":"D V Anand","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.jdiacomp.2016.07.008","article-title":"High osteoprotegerin is associated with development of foot ulcer in type 1\n                    diabetes","volume":"30","author":"E H Zobel","year":"2016","journal-title":"J Diabetes Complications"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1530\/eje.0.1490039","article-title":"Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients\n                    with microvascular complications","volume":"149","author":"S T Knudsen","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"S P Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2337\/dc18-1094","article-title":"The impact of liraglutide on diabetes-related foot ulceration and associated\n                    complications in patients with type 2 diabetes at high risk for Cardiovascular\n                    events: Results from the LEADER trial","volume":"41","author":"K Dhatariya","year":"2018","journal-title":"Diabetes Care"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"S P Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide\n                    in patients with type 2 diabetes (SURPASS-1): A double-blind, randomised, phase\n                    3 trial","volume":"398","author":"J Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2\n                    diabetes: A randomised, double-blind, placebo and active-controlled,\n                    parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"J Rosenstock","year":"2023","journal-title":"Lancet"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1007\/s00125-023-05988-3","article-title":"Incretins and microvascular complications of diabetes: Neuropathy, nephropathy,\n                    retinopathy and microangiopathy","volume":"66","author":"J Goldney","year":"2023","journal-title":"Diabetologia"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"926717","DOI":"10.3389\/fphar.2022.926717","article-title":"The outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2I) on\n                    diabetes-associated neuropathy: A systemic review and meta-analysis","volume":"13","author":"M Kandeel","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJMoa2303208","article-title":"Weekly icodec versus daily glargine U100 in type 2 diabetes without previous\n                    insulin","volume":"389","author":"J Rosenstock","year":"2023","journal-title":"N Engl J Med"},{"key":"ref41","first-page":"2154","article-title":"Worsening of diabetic retinopathy with rapid improvement in systemic glucose\n                    control: A review","author":"S C Bain","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.2337\/dc24-S012","article-title":"Retinopathy, neuropathy, and foot care: Standards for care in diabetes \u2013\n                    2024","volume":"47","author":"American Diabetes Association Professional Practice\n                            Committee","year":"2024","journal-title":"Diabetes Care"}],"container-title":["Experimental and Clinical Endocrinology &amp; Diabetes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2498-6826.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T23:52:47Z","timestamp":1741823567000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2498-6826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":41,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2025,3,12]]},"published-print":{"date-parts":[[2025,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2498-6826","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0947-7349","1439-3646"],"issn-type":[{"type":"print","value":"0947-7349"},{"type":"electronic","value":"1439-3646"}],"subject":[],"published":{"date-parts":[[2025,1,22]]}}}